The emergence of a novel human coronavirus, first reported from Saudi Arabia in September 2012, recently renamed the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has created global alarm because it is the causative agent of a severe and frequently fatal acute respiratory illness (SARI) resembling the illness caused by severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). All cases either occurred in the Middle East or had direct links to a primary case infected in the Middle East. MERS-CoV can cause sporadic infection, infection among families, and, of particular concern, infection among healthcare workers. Most patients who were initially infected with MERS-CoV had underlying comorbid medical conditions and laboratory testing showed that most of these cases had raised concentrations of lactate dehydrogenase and aspartate aminotransferase associated with thrombocytopenia and lymphopenia.The case fatality rate (CFR) in patients infected with MERS-CoV is high---estimated at 43% in 176 patients reported so far by World Health Organization (WHO). This rate is higher than that of SARS---estimated at 10%, and is strongly age- and sex-dependent. Although the source of virus in patients with sporadic infection remains unknown, although bats and camels have been implicated. Clear evidence of limited human-to-human transmission of MERS-CoV has now been documented in several case clusters, including particularly family members and patients in health care facilities, but all such clusters have, at least thus far, been limited in extent. However, a real concern persists that the virus will adapt to interhuman transmission and switch from an aborted epidemic to a pandemic similar to the SARS-CoV epidemic in 2003--2004. MERS-CoV is transmitted through droplets and contact. In the case of invasive respiratory procedures, MERS-CoV is transmitted through airborne route. Early diagnosis and strict implementation of the core components for infection prevention and control programs are crucial for preventing epidemic amplification.

The emergence of respiratory viruses that cause significant disease in human beings is a major risk to the global economy and the health of the human population. The potential effect of newly discovered viruses calls for a better understanding of the human--animal interface, the development of rapid diagnostic tests, and effective antiviral and immunomodulatory therapies. In the absence of an effective vaccine and a specific antiviral treatment, there is an urgent need to rapidly identify potential therapeutics.
